patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2 research hub

COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2 NEGATIVE BREAST CANCER AND A DELETERIOUS GERMLINE MUTATION IN BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 OR A HOMOLOGOUS RECOMBINATION DEFICIENCY

This study looks at new treatments for advanced breast cancer that has spread or can't be removed by surgery. It focuses on women with specific gene changes. Researchers are testing two drugs, pembrolizumab and olaparib, to see if they can shrink tumours and improve health.